BR112012003283A2 - sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, composição farmacêutica, produto, kit, uso de um sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, e, método de introdução de uma molécula de medicamento no citosol de uma célula em um paciente. - Google Patents

sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, composição farmacêutica, produto, kit, uso de um sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, e, método de introdução de uma molécula de medicamento no citosol de uma célula em um paciente.

Info

Publication number
BR112012003283A2
BR112012003283A2 BR112012003283A BR112012003283A BR112012003283A2 BR 112012003283 A2 BR112012003283 A2 BR 112012003283A2 BR 112012003283 A BR112012003283 A BR 112012003283A BR 112012003283 A BR112012003283 A BR 112012003283A BR 112012003283 A2 BR112012003283 A2 BR 112012003283A2
Authority
BR
Brazil
Prior art keywords
pharmaceutically acceptable
acceptable salt
photosensitizing agent
amphiphilic photosensitizing
amphiphilic
Prior art date
Application number
BR112012003283A
Other languages
English (en)
Other versions
BR112012003283A8 (pt
BR112012003283B1 (pt
Inventor
Anders Hogset
Jo Klaveness
Original Assignee
Pci Biotech As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pci Biotech As filed Critical Pci Biotech As
Publication of BR112012003283A2 publication Critical patent/BR112012003283A2/pt
Publication of BR112012003283A8 publication Critical patent/BR112012003283A8/pt
Publication of BR112012003283B1 publication Critical patent/BR112012003283B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR112012003283-6A 2009-08-14 2010-08-16 Sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, composição farmacêutica, kit para uso em um método de internalização fotoquímica e uso de um sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico BR112012003283B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0914287.8 2009-08-14
GBGB0914287.8A GB0914287D0 (en) 2009-08-14 2009-08-14 Compositions
PCT/GB2010/001547 WO2011018635A2 (en) 2009-08-14 2010-08-16 Photosensitizing compositions

Publications (3)

Publication Number Publication Date
BR112012003283A2 true BR112012003283A2 (pt) 2016-03-01
BR112012003283A8 BR112012003283A8 (pt) 2016-05-17
BR112012003283B1 BR112012003283B1 (pt) 2020-06-16

Family

ID=41171444

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012003283-6A BR112012003283B1 (pt) 2009-08-14 2010-08-16 Sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, composição farmacêutica, kit para uso em um método de internalização fotoquímica e uso de um sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico

Country Status (23)

Country Link
US (1) US9026203B2 (pt)
EP (1) EP2464384B1 (pt)
JP (1) JP5946407B2 (pt)
KR (1) KR101795362B1 (pt)
CN (1) CN102648004B (pt)
AU (1) AU2010283565B2 (pt)
BR (1) BR112012003283B1 (pt)
CA (1) CA2771021C (pt)
DK (1) DK2464384T3 (pt)
ES (1) ES2610143T3 (pt)
GB (1) GB0914287D0 (pt)
HR (1) HRP20161712T1 (pt)
LT (1) LT2464384T (pt)
ME (1) ME02616B (pt)
MX (1) MX337481B (pt)
NZ (1) NZ598380A (pt)
PL (1) PL2464384T3 (pt)
PT (1) PT2464384T (pt)
RS (1) RS55530B1 (pt)
RU (1) RU2574019C2 (pt)
SG (1) SG178420A1 (pt)
SI (1) SI2464384T1 (pt)
WO (1) WO2011018635A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0914286D0 (en) * 2009-08-14 2009-09-30 Pci Biotech As Method
GB0914287D0 (en) 2009-08-14 2009-09-30 Pci Biotech As Compositions
WO2013009701A2 (en) 2011-07-08 2013-01-17 The University Of North Carolina At Chapel Hill Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
GB201208548D0 (en) 2012-05-15 2012-06-27 Pci Biotech As Compound and method
EP2992000B1 (en) 2013-05-03 2020-07-08 The Regents of The University of California Cyclic di-nucleotide induction of type i interferon
AU2014314149B2 (en) * 2013-08-28 2019-12-19 Pci Biotech As Compound and method for vaccination and immunisation
WO2016061256A1 (en) * 2014-10-14 2016-04-21 The University Of Chicago Nanoparticles for photodynamic therapy, x-ray induced photodynamic therapy, radiotherapy, chemotherapy, immunotherapy, and any combination thereof
US10806694B2 (en) 2014-10-14 2020-10-20 The University Of Chicago Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof
GB201503776D0 (en) 2015-03-05 2015-04-22 Pci Biotech As Compound and method
KR101736149B1 (ko) * 2015-09-30 2017-05-17 (주)나노팜 여드름 피부개선을 위한 광민감성 물질을 함유한 건식다중캡슐형 조성물 및 그의 제조방법
US11246877B2 (en) 2016-05-20 2022-02-15 The University Of Chicago Nanoparticles for chemotherapy, targeted therapy, photodynamic therapy, immunotherapy, and any combination thereof
RU2019109682A (ru) 2016-10-14 2020-11-16 ПиСиАй БИОТЕК АС Лечение холангиокарциномы с применением tpcs-2-индуцированной фотохимической интернализации гемцитабина
WO2019028250A1 (en) 2017-08-02 2019-02-07 The University Of Chicago NOMOGENEOUS ORGANOMETALLIC ORGANOMETRIC ORGANOMETRIC LAYERS FOR X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, RODIODYNAMIC THERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION THEREOF
CN107722075A (zh) * 2017-10-09 2018-02-23 大连理工大学 一类二氢卟吩葡萄糖苷类化合物及其制备方法与应用
GB201718631D0 (en) 2017-11-10 2017-12-27 Pci Biotech As Method
RU2720799C1 (ru) * 2019-07-03 2020-05-13 Федеральное государственное унитарное предприятие "Государственный научный центр "Научно-исследовательский институт органических полупродуктов и красителей" Способ определения фракционного состава сульфированного фталоцианина алюминия
RU2757936C1 (ru) * 2021-03-12 2021-10-25 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ прогнозирования риска развития хронической истинной экземы на основе молекулярно-генетических данных

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582831A (en) * 1984-11-16 1986-04-15 Pfizer Inc. Anti-inflammatory polymorphic monoethanolamine salt of N-(2-pyridyl)-2-methyl-4-hydroxy-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide compound, composition, and method of use therefor
JPH0753861B2 (ja) * 1985-04-15 1995-06-07 味の素株式会社 紫外線吸収剤
US5284647A (en) 1988-03-18 1994-02-08 Schering Aktiengesellschaft Mesotetraphenylporphyrin complex compounds, process for their production and pharmaceutical agents containing them
US5292516A (en) 1990-05-01 1994-03-08 Mediventures, Inc. Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers
US5346703A (en) 1990-08-07 1994-09-13 Mediventures, Inc. Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
IT1254045B (it) * 1991-12-31 1995-09-06 Lifegroup Spa Derivati idrosolubili della biotina e relative composizioni terapeutiche
US5389681A (en) 1992-10-22 1995-02-14 Ciba-Geigy Corporation Parenteral solutions for diclofenac salts
FR2700543B1 (fr) * 1993-01-15 1995-03-17 Synthelabo Sels de dérivés de 4-pyrimidinone, leur préparation et leur application en thérapeutique.
DE4305523A1 (de) 1993-02-17 1994-08-18 Diagnostikforschung Inst Meso-Tetraphenylporphyrin-Komplexverbindungen, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel
NO180167C (no) 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
US6540981B2 (en) 1997-12-04 2003-04-01 Amersham Health As Light imaging contrast agents
US6992107B1 (en) 1995-03-10 2006-01-31 Photocure Asa Esters of 5-aminolevulinic acid and their use as photosensitizing compounds in photochemotherapy
DE69817529T2 (de) 1998-02-19 2004-06-24 Microflow Engineering S.A. Vorrichtung und Gerät zur intrakavitären Wirkstofffreigabe während videounterstützter Chirurgie oder anderer endoskopischer Verfahren
GB9905911D0 (en) 1999-03-15 1999-05-05 Photocure As Method
US6398748B1 (en) 1999-03-16 2002-06-04 Robert B. Wilson Splint bandage and method
US6570013B2 (en) * 2000-02-16 2003-05-27 Pfizer Inc Salts of zopolrestat
EP1339862B1 (en) 2000-11-29 2014-01-08 PCI Biotech AS Photochemical internalization for virus-mediated molecule delivery into the cytosol
HU229805B1 (en) 2000-11-29 2014-07-28 Pci Biotech As Photochemical internalization for delivery of molecules into the cytosol
GB0118251D0 (en) 2001-07-26 2001-09-19 Photocure Asa Method
GB0121023D0 (en) * 2001-08-30 2001-10-24 Norwegian Radium Hospital Res Compound
US7541457B2 (en) 2003-05-14 2009-06-02 Universite De Sherbrooke Amphiphilic trisulfonated porphyrazines for photodynamic applications in medicine
GB0415263D0 (en) 2004-07-07 2004-08-11 Norwegian Radium Hospital Res Method
GB2420784A (en) * 2004-11-25 2006-06-07 Pci Biotech As Phototherapeutic amphiphilic phthalocyanine-based compounds where 1 peripheral ring system is more hydrophilic & has more hydrophilic groups than the other 3
GB0514743D0 (en) * 2005-07-19 2005-08-24 Astrazeneca Ab Salt
EP1933810B1 (en) 2005-08-11 2012-10-10 Massachusetts Institute of Technology Intravesical drug delivery device and method
GB0605743D0 (en) * 2006-03-22 2006-05-03 Oxagen Ltd Salts with CRTH2 antagonist activity
JP2008095050A (ja) * 2006-10-16 2008-04-24 Hidetoshi Tsuchida アルブミン−金属ポルフィリン複合体および光増感剤
GB0811955D0 (en) 2008-06-30 2008-07-30 Pci Biotech As Method
GB0914286D0 (en) * 2009-08-14 2009-09-30 Pci Biotech As Method
GB0914287D0 (en) 2009-08-14 2009-09-30 Pci Biotech As Compositions

Also Published As

Publication number Publication date
MX2012001953A (es) 2012-03-29
EP2464384A2 (en) 2012-06-20
GB0914287D0 (en) 2009-09-30
HRP20161712T1 (hr) 2017-04-21
RU2012109559A (ru) 2013-09-20
JP5946407B2 (ja) 2016-07-06
KR20120094900A (ko) 2012-08-27
SG178420A1 (en) 2012-04-27
ES2610143T3 (es) 2017-04-26
CA2771021A1 (en) 2011-02-17
CA2771021C (en) 2018-02-20
LT2464384T (lt) 2017-04-10
MX337481B (es) 2016-03-08
PT2464384T (pt) 2017-01-12
BR112012003283A8 (pt) 2016-05-17
PL2464384T3 (pl) 2017-06-30
SI2464384T1 (sl) 2017-04-26
RS55530B1 (sr) 2017-05-31
CN102648004B (zh) 2015-07-22
CN102648004A (zh) 2012-08-22
RU2574019C2 (ru) 2016-01-27
ME02616B (me) 2017-06-20
US9026203B2 (en) 2015-05-05
EP2464384B1 (en) 2016-10-12
KR101795362B1 (ko) 2017-11-08
WO2011018635A3 (en) 2011-07-07
US20120226217A1 (en) 2012-09-06
JP2013501769A (ja) 2013-01-17
AU2010283565A1 (en) 2012-03-15
WO2011018635A2 (en) 2011-02-17
NZ598380A (en) 2014-04-30
AU2010283565B2 (en) 2015-12-10
BR112012003283B1 (pt) 2020-06-16
DK2464384T3 (en) 2017-01-23

Similar Documents

Publication Publication Date Title
BR112012003283A8 (pt) sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, composição farmacêutica, produto, kit, uso de um sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, e, método de introdução de uma molécula de medicamento no citosol de uma célula em um paciente.
IL274602A (en) Pharmaceutical tablets containing eltrombopag olamine, methods for their preparation and use thereof in the preparation of medicaments for treating thrombocytopenia
EP2395834A4 (en) Sodium nitrite-containing pharmaceutical compositions
WO2007092620A3 (en) Stable formulations, and methods of their preparation and use
JP2007527914A5 (pt)
IL206952A (en) History of Aminodia Hydrothiazine, medicinal preparations containing them, and their use in the preparation of medicines
BRPI0814666A2 (pt) composição farmacêutica para a administração oral, uso de uma formulação. processo para a preparação de uma forma de dosagem sólida, e, forma de dosagem sólida
PL2371853T3 (pl) Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, kompozycja farmaceutyczna, zastosowanie pochodnej insuliny lub jej farmaceutycznie dopuszczalnej soli oraz sposób leczenia
CL2009000035A1 (es) Compuestos derivados 3-espiro-heterociclo-1il-5h-ciclopentan[d]pirimidin-indol, util para inhibir la actividad de akt quinasa; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de enfermedades tal como cancer, fibrosis quistica, diabetes, enfermedad de alzheimer, entre otras.
WO2011157741A3 (en) Human antibody drug conjugates against tissue factor
BRPI0923589A2 (pt) uso de uma composição espumável essencialmente livre de ingredientes farmaceuticamente ativos para o tratamento da pele humana.
BR112014002718A8 (pt) célula, população de célula, composição farmacêutica e kit para uso no tratamento de uma doença de degeneraçãoretinal
IL208832A (en) 3-Aminocarbazole Compound, Pharmaceutical Preparations Containing Them, Methods of Preparation and Use for Drug Preparation
IL198314A (en) History of Quinuclidine of (hetero) Acrylic Cyclohepethecarboxylic Acid, Process of Preparation, Medicinal Preparations Containing Them and Use of Drug Preparation for Treatment
BRPI0812738A2 (pt) Composto, sal farmceuticamente aceitável, composição farmacêutica, uso de um composto, e, método par ao tratamento de uma infecção viral em um humano
IL203936A (en) HISTORY 4 - Pyrimidinsulfamide, Process for Preparation, Pharmaceutical Preparations Containing and Using it for Medication Preparation
NO20085420L (no) Farmasøytisk formulering med fenylefrin og preparater for absorpsjon i tykktarmen
PT2364983E (pt) Novo derivado tricíclico ou seus sais farmaceuticamente aceitáveis, seu método de preparação, e composição farmacêutica que o contém
PL2760878T3 (pl) Pochodne estra-1,3,5(10),16-tetraeno-3-karboksyamidowe, sposób ich wytwarzania, preparaty farmaceutyczne, które je zawierają, i ich zastosowanie do wytwarzania leków
BRPI1009392A2 (pt) "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica."
BR112012003280A2 (pt) composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto.
CL2007001648A1 (es) Compuesto derivado de leptomicina; conjugado que comprende agente de unión a células unido a uno o mas de dichos derivados; composiciones farmacéuticas que comprenden dicho derivado o conjugado; util en el tratamiento del cancer; proceso de preparacion de un compuesto o de un conjugado de un derivado de leptomicina.
SI1909843T1 (sl) Protitumorski biokonjugati hialuronske kisline ali njenih derivatov, dobljeni z indirektno kemijsko konjugacijo, in njihova uporaba na farmacevtskem področju
DE602009000873D1 (de) Diosmetin-Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
IL207972A (en) History of pyridine-2-ram, pharmaceuticals containing them and their use in the preparation of medicines

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/08/2010, OBSERVADAS AS CONDICOES LEGAIS.